We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Levrett | LSE:LVRT | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMLVRT
RNS Number : 7948C
Levrett PLC
20 April 2017
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE UNITED STATES OF AMERICA OR SOUTH AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.
For Immediate Release 20 April 2017
Levrett Plc
("Levrett" or "the Company")
Convertible Loan Agreement
Levrett, a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, announces that it has entered into a Convertible Loan Agreement for GBP200,000 ("Loan") with a private investor.
The Loan is for a fixed term of 12 months and carries interest at 9% per annum, which the Lender can elect to convert. The Loan is convertible into new Ordinary Shares in the Company at a price of 4 pence per share ("Conversion"), and following Conversion the Lender will be granted a one-for-one warrant to subscribe for new ordinary shares at 4 pence per share, exercisable for a period of three years from Conversion. Under the terms of the Loan, the Lender will advance the total sum to the Company within three business days.
The proceeds from the Loan are to be used for general working capital and to support Nuformix Limited in the short-term pending completion of the potential reverse takeover as announced by the Company on 16 September 2016. The acquisition remains conditional, inter alia, on consent from the UK Listing Authority for the readmission of the combined entity to the Standard List.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
Enquiries:
Levrett Plc Pascal Hughes, CEO +44 (0) 20 7183 4342 Whitman Howard Limited (Broker and Corporate Advisor) Niall Baird / Nick Lovering +44 (0) 20 7659 1234 Gable Communications Limited +44 (0) 20 7193 7463 (Financial PR) +44 (0) 7872 061007 John Bick e: levrett@gablecommunications.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IODGMGMDMLVGNZZ
(END) Dow Jones Newswires
April 20, 2017 02:00 ET (06:00 GMT)
1 Year Levrett Chart |
1 Month Levrett Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
